Table 3 Association between cardiac function parameters and Torsades de Point (TdP) risk category of antipsychotics
AP Torsades de Point risk category, N (%) | |||||
|---|---|---|---|---|---|
Monitoring parameters | A | B | C | χ 2 | P-value |
Presence of ECG testing before AP treatment | 48 (29.6) | 229 (20.0) | 3 (1.1) | 12.9 | 0.002 |
Presence of ECG testing during AP treatment | 46 (28.4) | 375 (32.8) | 16 (38.1) | 1.9 | 0.3 |
Presence of electrolytes levels before AP treatment | 47 (29.0) | 246 (21.5) | 2 (4.8) | 12.1 | 0.002 |
Presence of electrolytes levels during AP treatment | 51 (31.5) | 358 (31.3) | 18 (42.9) | 2.5 | 0.3 |
Presence of personal history of pre-existing cardiac disease | 5 (3.1) | 57 (5.0) | 4 (9.5) | 3.1 | 0.2 |
Number of cardiac function parameters tested | |||||
0 | 63 (38.9) | 519 (45.4) | 20 (47.6) | 10.3a | 0.41a |
1 | 27 (16.7) | 190 (16.6) | 5 (11.9) | ||
2 | 55 (34.0) | 298 (26.0) | 13 (31.0) | ||
3 | 8 (4.9) | 73 (6.4) | 4 (9.5) | ||
4 | 9 (5.6) | 56 (4.9) | 0 (0.0) | ||
5 | 0 (0.0) | 8 (0.0) | 0 (0.0) | ||